Portal de investigación
Real-World Experience With Secukinumab for Hidradenitis Suppurativa: A Multicenter Retrospective Analysis of 263 Patients From the SECU-SPAIN Study.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Martorell A
- Vilarrasa-Rull E
- Fernandez-Crehuet P
- Molina-Leyva A
- Garcia-Ruiz R
- Garbayo-Salmons P
- Ortiz-Salvador JM
- Alfageme-Roldan F
- Garcias-Ladaria J
- Bassas-Vila J
- Fuertes-de-Vega I
- Carnero-Gonzalez L
- Almenara-Blasco M
- Aguayo-Ortiz R
- Gil Pallares P
- Fornons-Servent R
- Gracia-Darder I
- Mora-Fernández V
- Corral O
- Pericet-Fernandez L
- Haselgruber S
- Ochando-Ibernon G
- Menéndez-Parron A
- Masferrer E
- Gamissans M
- Solera-Talamante M
- Moya M
- Imbernon A
- Melgosa J
- Spanish Hidradenitis Suppurativa Group (GEHS)
Grupos
Abstract
BACKGROUND/OBJECTIVE: There is no consensus on the response rates of secukinumab, as findings from phase III trials differ from those reported in clinical-practice studies. This study aimed to assess the mid-term safety and efficacy profile of secukinumab in patients with moderate-to-severe Hidradenitis suppurativa (HS). METHODS: This retrospective, multicenter study included patients with moderate-to-severe HS treated with secukinumab (300mg every four weeks) between 2020 and 2024. Eligible patients were aged =18 years, with a clinical diagnosis of moderate-to-severe HS, and a minimum follow-up of 24 weeks. Key exclusions included patients treated with nonstandard secukinumab dosing regimens or those with insufficient clinical data. The primary endpoints were achievement of HiSCR50 (=50% reduction in the combined count of nodules and abscesses) at weeks 16 and 24). Secondary endpoints included achieving a =55% reduction in the International HS Severity Score (IHS4-55) and adverse events. RESULTS: A total of 263 patients (49.4%, women; 50.6%, men; mean age, 41.8±13.2 years) were included. The most common HS phenotype was mixed (49.4%), and 55.1% had Hurley stage III disease. At weeks 16 and 24, a total of 57.4% and 63.6% of patients achieved HiSCR50, respectively. The mean IHS4 score dropped significantly from 16.7±10.0 at baseline to 7.6±5.6 at week 24 (p<0.0001). At weeks 16 and 24, 52% and 56% of patients achieved an IHS4-55 response. Secukinumab was discontinued in 14.5% of patients because of lack of efficacy or adverse events. CONCLUSIONS: Secukinumab demonstrated a significant safety and efficacy profile for patients with moderate-to-severe in a real-world setting, with better outcomes than those reported in earlier clinical trials. Response evaluation at both week 16 and 24 is crucial due to variations in treatment effectiveness.
Copyright © 2025 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 0001-7310, 1578-2190
- Tipo:
- Article
- Páginas:
- 104562-104562
- PubMed:
- 41391709
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 0,279 SCImago ℠
- Cuartil:
- Q3 SCImago ℠
Actas Dermo-Sifiliograficas ELSEVIER ESPANA
Citas Recibidas en Web of Science: 1
Documentos
Filiaciones
Keywords
- Anti Il17A; HS; Monoclonal antibody; Real-world evidence; Secukinumab
Cita
Martorell A,Vilarrasa E,Fernandez P,Molina A,MANSILLA M,Garcia R,Garbayo P,Ortiz JM,Alfageme F,Garcias J,Bassas J,Fuertes I,Carnero L,Almenara M,TORRES I,Aguayo R,Gil P,Fornons R,Gracia I,Mora V,Corral O,Pericet L,NAVARRO F,Haselgruber S,Ochando G,Menéndez A,Masferrer E,Gamissans M,Solera M,Moya M,Imbernon A,Melgosa J,Spanish Hidradenitis Suppurativa Group (. Real-World Experience With Secukinumab for Hidradenitis Suppurativa: A Multicenter Retrospective Analysis of 263 Patients From the SECU-SPAIN Study. Actas Dermo-Sifilogr. 2026. 117. (4):p. 104562-104562. IF:2,900. (2).